Every material Form 8-K PALISADE BIO, INC. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Palisade Bio reported second-quarter 2026 results, with a net loss of $10.6 million, up from $2.8 million a year earlier, as research and development and general and administrative expenses rose sharply. The company is preparing to start the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026, and it had $125.2 million in cash and cash equivalents as of June 30, 2026.
Net loss was $10.6 million, or $0.05 per share, for the three months ended June 30, 2026, versus $2.8 million, or $0.58 per share, a year earlier.
Research and development expenses rose to $7.4 million from $1.7 million, and general and administrative expenses rose to $4.8 million from $1.2 million.
License revenue of $0.5 million was recognized from a milestone under the Newsoara co-development agreement; none was recognized in the prior-year quarter.
Cash and cash equivalents were $125.2 million at June 30, 2026, which the company says should fund operations through its key Phase 2 readouts, expected in the second half of 2027 and early 2028.
Palisade Bio expanded its board from five to six directors and appointed Jordan Zwick, effective June 10, 2026, who also joined the Audit Committee. At its June 10 annual meeting, stockholders also approved raising authorized common stock from 300,000,000 to 450,000,000 shares, and the amendment took effect on filing with Delaware on June 11, 2026.
Jordan Zwick appointed to the board on June 10, 2026, and to the Audit Committee; the board determined he is independent
Non-employee director initial grant of restricted stock units with a grant value of $566,000, vesting in three equal annual installments
Authorized common stock increased from 300,000,000 to 450,000,000 shares; stockholders approved it with 128,093,623 votes for and 871,548 against
Stockholders also approved the amended and restated 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan
Palisade Bio reported a first-quarter 2026 net loss of $9.6 million, up from $2.2 million a year earlier, as research and development and general and administrative expenses rose sharply. The company had $132.6 million in cash and cash equivalents at March 31, 2026, and said it expects that cash to fund operations through its Phase 2 ulcerative colitis and Crohn's disease readouts, but the filing reports no revenue and a much larger loss for shareholders.
Net loss was $9.6 million, or $0.05 per share, for the three months ended March 31, 2026, versus $2.2 million, or $0.47 per share, a year earlier.
Research and development expenses rose to $6.4 million from $1.0 million; general and administrative expenses rose to $4.4 million from $1.4 million.
Cash and cash equivalents were $132.6 million at March 31, 2026, down from $133.4 million at December 31, 2025.
Phase 2 ulcerative colitis trial initiation is targeted for Q3 2026, and the Phase 2 UC readout is expected in 2H 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PALISADE BIO, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →